Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 5/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690561 | 1.00 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL25750639 | 0.85 | NPC1 (0.52) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL22230885 | 0.84 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL207723 | 0.84 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL5328071 | 0.81 | NPC1 (0.48) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL27028728 | 0.80 | APP (0.45) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL14700006 | 0.79 | APP (0.47) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL20607781 | 0.78 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL29859226 | 0.77 | CCR5 (0.63) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL5628127 | 0.77 | CCR5 (0.63) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-01-05 | — | — | US | disclosed |
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-01-05 | — | — | US | disclosed |
| CN-114585609-A | 2H-indazole derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3990432-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020263967-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020263967-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | ALDH1A1 1071/4885SMN1; SMN2 1182/4885LMNA 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.